CR20220493A - Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades - Google Patents

Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades

Info

Publication number
CR20220493A
CR20220493A CR20220493A CR20220493A CR20220493A CR 20220493 A CR20220493 A CR 20220493A CR 20220493 A CR20220493 A CR 20220493A CR 20220493 A CR20220493 A CR 20220493A CR 20220493 A CR20220493 A CR 20220493A
Authority
CR
Costa Rica
Prior art keywords
chromenone
phosphoinositide
allosteric
pi3k
kinase
Prior art date
Application number
CR20220493A
Other languages
English (en)
Inventor
Nicholas A Boyles
Aleksey I Gerasyuto
Eugene R Hickey
Christopher Glenn Mayne
Daniel Lee Severance
Tien Widjaja
Shulu Feng
Erin Danielle Anderson
Sean Douglas Aronow
Jennifer Lynn Knight
Manoj Kumar
Loredana Puca
Thomas Combs Irvin
David L Mcelligott
Markus K Dahlgren
Katelyn Frances Long
Michael Brian Welch
Edward A Kesicki
Anke Klippel-Giese
Gabrielle R Kolakowski
Johnathan Alexander Mclean
Kannan Karukurichi Ravi
Original Assignee
Petra Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Petra Pharma Corp filed Critical Petra Pharma Corp
Publication of CR20220493A publication Critical patent/CR20220493A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La descripción se refiere a los compuestos de la Fórmula (I) como inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (PI3K) útiles en el tratamiento de enfermedades o trastornos asociados con la modulación del PI3K, Fórmula (I): (I), o un profármaco, solvato, enantiómero, estereoisómero, tautómero o sal farmacéuticamente aceptable de este, en donde <strong>R<sub>1,</sub> R<sub>2,</sub> R<sub>3,</sub> R<sub>4,</sub> R<sub>5,</sub> R<sub>6,</sub> R<sub>7,</sub> R<sub>8,</sub> R<sub>9,</sub> W, X, Y, s, </strong>y el <strong>Anillo A</strong> son como se describen en la presente descripción.
CR20220493A 2020-04-03 2021-04-02 Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades CR20220493A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063005096P 2020-04-03 2020-04-03
PCT/US2021/025521 WO2021202964A1 (en) 2020-04-03 2021-04-02 Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of diseases associated with p13k modulation

Publications (1)

Publication Number Publication Date
CR20220493A true CR20220493A (es) 2022-12-15

Family

ID=75674963

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220493A CR20220493A (es) 2020-04-03 2021-04-02 Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades

Country Status (18)

Country Link
US (2) US11649227B2 (es)
EP (1) EP4126851A1 (es)
JP (1) JP7505023B2 (es)
KR (1) KR20220163462A (es)
CN (1) CN115956075A (es)
AR (1) AR121719A1 (es)
AU (1) AU2021248415B2 (es)
BR (1) BR112022019918A2 (es)
CA (1) CA3173569A1 (es)
CO (1) CO2022014160A2 (es)
CR (1) CR20220493A (es)
EC (1) ECSP22077299A (es)
IL (1) IL296918A (es)
JO (1) JOP20220247A1 (es)
MX (1) MX2022012306A (es)
PE (1) PE20230824A1 (es)
TW (1) TWI794780B (es)
WO (1) WO2021202964A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR121719A1 (es) 2020-04-03 2022-06-29 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
BR112023022940A2 (pt) 2021-05-03 2024-01-23 Petra Pharma Corp Inibidores alostéricos de cromenona de fosfoinositídeo 3-quinase (pi3k) para o tratamento de doenças
AU2022282380A1 (en) 2021-05-27 2023-12-07 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of cancer
WO2023081209A1 (en) * 2021-11-03 2023-05-11 Zeno Management, Inc. Pi3k inhibitors and methods of treating cancer
CA3237760A1 (en) * 2021-12-08 2023-06-15 Xiaolin Hao Fused heterocyclic compounds as pi3kalpha inhibitors
TW202340202A (zh) * 2021-12-22 2023-10-16 美國加利福尼亞大學董事會 Gtp酶抑制劑及其用途
US20240124422A1 (en) * 2022-03-29 2024-04-18 Prelude Therapeutics Incorporated Mutant pi3k-alpha inhibitors and their use as pharmaceuticals
WO2023205680A1 (en) * 2022-04-20 2023-10-26 Synnovation Therapeutics, Inc. PI3Kα INHIBITORS
WO2023207881A1 (en) * 2022-04-24 2023-11-02 InventisBio Co., Ltd. Compounds, preparation methods and uses thereof
JP2023164409A (ja) * 2022-04-29 2023-11-10 ペトラ・ファーマ・コーポレイション 疾患の治療用のホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリッククロメノン阻害剤
WO2023239710A1 (en) 2022-06-08 2023-12-14 Onkure, Inc. Benzopyrimidin-4(3h)-ones as pi3k inhibitors
CN117362281A (zh) * 2022-07-07 2024-01-09 海创药业股份有限公司 一种pi3k抑制剂及其制备方法和用途
WO2024054469A1 (en) 2022-09-08 2024-03-14 Onkure, Inc. Isoquinolones as pi3k inhibitors
WO2024051778A1 (en) * 2022-09-09 2024-03-14 InventisBio Co., Ltd. Compounds, preparation methods and uses thereof
WO2024064024A1 (en) 2022-09-19 2024-03-28 Onkure, Inc. ((4-oxo-3,4-dihydroquinazolin-8-yl)methyl)amine derivatives as p13k inhibitors for the treatment of cancer
WO2024081345A1 (en) 2022-10-14 2024-04-18 Onkure, Inc. Benzopyrimidin-4(3h)-ones as pi3k inhibitors
WO2024081904A1 (en) * 2022-10-14 2024-04-18 Genesis Therapeutics, Inc. Methods for treating cancer
WO2024097172A1 (en) * 2022-11-01 2024-05-10 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
WO2024097205A1 (en) * 2022-11-02 2024-05-10 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
WO2024097721A1 (en) 2022-11-02 2024-05-10 Petra Pharma Corporation Targeting allosteric and orthosteric pockets of phosphoinositide 3-kinase (pi3k) for the treatment of disease
WO2024099437A1 (en) * 2022-11-11 2024-05-16 Fochon Biosciences, Ltd. Compounds as protein kinase inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1190405B (it) 1985-10-22 1988-02-16 Recordati Chem Pharm Derivati del flavone
IL89840A (en) 1988-04-06 1996-10-31 Lipha Substituted flavonoid compounds and salts thereof their preparation and pharmaceutical composition containing them
EP0459983A1 (en) 1988-12-21 1991-12-11 PHARMACIA &amp; UPJOHN COMPANY Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
AU2001230426C1 (en) 2000-01-24 2006-06-22 Astrazeneca Ab Therapeutic morpholino-substituted compounds
US7884127B2 (en) 2002-07-08 2011-02-08 Pirimal Life Sciences Ltd. Inhibitors of cyclin dependent kinases and their use
TWI331034B (en) 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
NZ538420A (en) 2002-08-16 2007-06-29 Kinacia Pty Ltd Inhibition of phosphoinositide 3-kinase beta
ES2511942T3 (es) 2008-09-29 2014-10-23 Glaxosmithkline Llc Análogos de cromenona como moduladores de sirtuina
US8399460B2 (en) 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
ES2651682T3 (es) * 2009-11-05 2018-01-29 Rhizen Pharmaceuticals S.A. Moduladores de cinasa novedosos
CN106008479B (zh) * 2015-03-06 2020-01-10 南京圣和药业股份有限公司 作为磷脂酰肌醇3-激酶δ抑制剂的取代嘧啶类化合物及其应用
CA3017366A1 (en) 2016-03-11 2017-09-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Icariin and icaritin derivatives
CN108299365B (zh) 2018-01-31 2021-08-06 中南大学 一种黄酮衍生物及其应用
AR121719A1 (es) 2020-04-03 2022-06-29 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades

Also Published As

Publication number Publication date
AU2021248415A1 (en) 2022-10-20
TWI794780B (zh) 2023-03-01
ECSP22077299A (es) 2023-01-31
US20220372023A1 (en) 2022-11-24
US11649227B2 (en) 2023-05-16
IL296918A (en) 2022-12-01
PE20230824A1 (es) 2023-05-19
JP7505023B2 (ja) 2024-06-24
JP2023521321A (ja) 2023-05-24
EP4126851A1 (en) 2023-02-08
TW202200567A (zh) 2022-01-01
AR121719A1 (es) 2022-06-29
AU2021248415B2 (en) 2024-03-21
WO2021202964A1 (en) 2021-10-07
CN115956075A (zh) 2023-04-11
CO2022014160A2 (es) 2023-02-16
US20230286960A1 (en) 2023-09-14
BR112022019918A2 (pt) 2023-02-14
MX2022012306A (es) 2023-01-04
CA3173569A1 (en) 2021-10-07
KR20220163462A (ko) 2022-12-09
JOP20220247A1 (ar) 2023-01-30

Similar Documents

Publication Publication Date Title
CR20220493A (es) Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
CR20230517A (es) Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
IL308191A (en) Allosteric chromanone inhibitors of PHOSPHOINOSITIDE 3-KINASE (PI3K) for the treatment of diseases
ECSP18094983A (es) Derivados de pirazol como inhibidores de la calicreína plasmática
MX2020006128A (es) Inhibidores de la proteina de activacion de fibroblastos.
GEP20237519B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
MX2021010701A (es) Compuestos, composiciones y metodos para el tratamiento de enfermedad.
MX2007005546A (es) Tiazoles de 5-heteroarilo y su uso como inhibidores p13k.
GEP20227406B (en) Chromane monobactam compounds for the treatment of bacterial infections
WO2020132661A3 (en) Inhibitors of fibroblast activation protein
AU2019310335A8 (en) Methods of treating cancer with PI3K inhibitor, GDC-0077
MX2020012347A (es) Inhibidor que contiene derivado triciclico, metodo de preparacion del mismo y aplicacion del mismo.
MX2022015410A (es) Inhibidores de las cinasas receptoras del factor de crecimiento de fibroblastos.
ZA202210888B (en) Mtorc1 modulators and uses thereof
MX2022015679A (es) Inhibidor de tyk-2.
MX2022000545A (es) Inhibidores de enzimas.
WO2023122260A3 (en) Inhibitors of sars-cov-2
MX2022000733A (es) Derivados cannabinoides como compuestos farmaceuticamente activos y metodos de preparacion de los mismos.
BR112021019876A2 (pt) Inibidores de pde9 para tratar anemia falciforme
MX2021015403A (es) Terapia de combinacion que comprende un conjugado de anticuerpo-farmaco anti-cd19 y un inhibidor de pi3k o un agente secundario.
WO2020086954A3 (en) Treatments for charcot-marie-tooth disease
CA3199014A1 (en) Combination therapy for the treatment of a liver disease
MX2022015074A (es) Tratamiento antiviral.
WO2022115381A8 (en) Compositions and methods for treating cns disorders
MX2022011844A (es) Terapia combinada con un inhibidor de idh mutante.